July 29, 2003Circulation
Regression of Electrocardiographic Left Ventricular Hypertrophy by Losartan Versus Atenolol
Key result
Losartan-based therapy resulted in greater regression of ECG left ventricular hypertrophy by Cornell product (-200 vs -69 mm.ms, P<0.001) than atenolol-based therapy at 6 months.
Why the study?
Does losartan-based therapy improve regression of ECG LVH compared to atenolol-based therapy in hypertensive patients with ECG LVH?
Population
9,193 hypertensive patients with ECG LVH by Sokolow-Lyon voltage or Cornell voltage-duration product…
Comparison
Blinded losartan-based therapy evaluated at 6… vs Blinded atenolol-based therapy evaluated at 6…
Design
RCT, blinded
Follow-up
up to 5 years
Authors
Discussion
Loading...
Member takes
Implication
Losartan-based therapy should be prioritized over atenolol for ECG LVH regression in hypertension; confirms ARB superiority independent of BP reduction.
Study Design
Type
RCT (n=9,193)
Blinding
Blinded
Structured PICO
Does losartan-based therapy improve regression of ECG LVH compared to atenolol-based therapy in hypertensive patients with ECG LVH?
P
Population
9,193 hypertensive patients with ECG LVH by Sokolow-Lyon voltage or Cornell voltage-duration product criteria enrolled in the LIFE Study.
I
Intervention
Blinded losartan-based therapy evaluated at 6 months and annually up to 5 years.
C
Comparator
Blinded atenolol-based therapy evaluated at 6 months and annually up to 5 years.
O
Outcome
Regression of ECG LVH by Cornell voltage-duration product and Sokolow-Lyon voltage criteria.surrogate
Main Result
Absolute Event Rate: -200% vs -69%
p-value: p=<0.001
Losartan-based therapy is superior to atenolol-based therapy for regressing electrocardiographic left ventricular hypertrophy in hypertensive patients, independent of blood pressure reduction.
Cite This Study
Okin et al. (2003) conducted an RCT in Hypertension with ECG left ventricular hypertrophy (n=9,193). Losartan-based therapy vs. Atenolol-based therapy was evaluated on Regression of ECG left ventricular hypertrophy by Cornell voltage-duration product at 6 months (p=<0.001). Losartan-based therapy resulted in greater regression of ECG left ventricular hypertrophy by Cornell product (-200 vs -69 mm.ms, P<0.001) than atenolol-based therapy at 6 months.